Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials
click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.


Alan Franciscus

Editor-in-Chief

HCV Advocate



Showing posts with label access to care. Show all posts
Showing posts with label access to care. Show all posts

Sunday, June 21, 2015

Canada: Ontario urged to provide better access to breakthrough hepatitis C drugs

People infected with potentially fatal hepatitis C from tainted blood are pushing Ontario to make them whole by paying for expensive breakthrough drugs considered a virtual cure for the liver disease.

Ontario’s health ministry says 341 Ontarians with stage-two liver disease or worse get Sovaldi or Harvoni pills funded by taxpayers — $60,000 for a 12-week course — under an exceptional access program.

The medications are light-years ahead of previous pharmaceuticals that had troubling side effects and did not work nearly as well.

Doctors say the triage system, in which a FibroScan (a non-invasive liver test) must meet or exceed a specific level of liver damage, can miss patients with complications that would otherwise make them eligible for taxpayer coverage.

Read more...